drugset / Trial / NCT00401024

Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma

NCT00401024

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Collecting samples of tumor tissue and blood from patients with cancer to study in the laboratory may help doctors learn how patients respond to treatment. PURPOSE: This clinical trial is looking at tumor tissue samples from patients receiving imatinib mesylate for malignant glioma to see how much imatinib mesylate is found in the tumor tissue.

Timeline

Start
2006-10-12
Primary completion
2008-02-04
Completion
2008-11-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Imatinib Small molecule 600 mg Oral